Multicentre comparative study of neural epidermal growth factor-like 1 protein vs M-type phospholipase A2 receptor-associated membranous nephropathy

Table 1 Baseline characteristics of the cohort and treatment regimen followed, n (%)

Variable	Total (n = 41)	NELEL1-MN (n = 17)	PLA2R-MN (n = 24)	P value
Age (years), mean ± SD	42.6 ± 14.7	42.2 ± 16.9	42.8 ± 13.3	0.88
Male sex	15 (36.6)	4 (23.5)	11 (45.8)	0.14
Diabetes mellitus	6 (14.6)	1 (5.9)	5 (20.8)	0.18
Hypertension	14 (34.1)	6 (35.3)	8 (33.3)	0.90
TIM intake	15 (37.5)	12 (70.6)	3 (13.0)	< 0.001
Follow-up (months), median (IQR)	16 (12-24)	13 (12-19)	19.5 (12-24.5)	0.21
Disease association
Malignancy	2 (4.9)	0 (0)	2 (8.3)	0.22
Rheumatoid arthritis	2 (4.9)	2 (11.8)	0 (0)	0.08
Hypothyroidism	4 (10.5)	2 (13.3)	2 (8.7)	0.65
Psoriasis	1 (2.4)	1 (5.9)	0 (0)	0.23
HBV	0 (0)	0 (0)	0 (0)	-
HCV	0 (0)	0 (0)	0 (0)	-
HIV	0 (0)	0 (0)	0 (0)	-
SLE	0 (0)	0 (0)	0 (0)	-
Baseline laboratory parameters
Urine PCR (g/g), mean ± SD, median (IQR)	9.2 (5.2), 8.3 (4.7-12.5)	9.3 (5.9), 7.5 (6.9-11.7)	9.02 (4.8), 9.3 (4.4-13.2)	0.86, 0.91
eGFR (mL/minute/1.73 m2), mean ± SD, median (IQR)	106 (23.2), 107 (95-119)	112 (20.3), 117 (101-127)	102 (24.6), 102 (90-116)	0.17, 0.09
Serum albumin (g/dL), mean ± SD, median (IQR)	2.5 (0.7), 2.5 (1.9-3.1)	2.5 (0.9), 3 (1.7-3.4)	2.5 (0.6), 2.4 (2.1-3)	0.82, 0.67
Treatment followed
Supportive only	6 (16.6)	5 (29.4)	1 (4.1)	0.02
Cyclophosphamide + steroid	18 (43.9)	7 (41.2)	11 (45.8)	0.76
Rituximab	11 (26.3)	4 (23.5)	7 (29.2)	0.69
Calcineurin inhibitors	6 (14.7)	1 (5.9)	5 (20.3)	0.18

NELL1-MN: Neural epidermal growth factor-like 1 protein-associated membranous nephropathy; PLA2R-MN: M-type phospholipase A2 receptor-associated membranous nephropathy; IQR: Interquartile range; HBV: Hepatitis B virus; HCV: Hepatitis C virus; HIV: Human immunodeficiency virus; SLE: Systemic lupus erythematosus; PCR: Protein creatinine ratio; eGFR: Estimated glomerular filtration rate.